Skip to content
Feraheme, Rienso(ferumoxytol)
Feraheme, Rienso (ferumoxytol) is an unknown pharmaceutical. Ferumoxytol was first approved as Feraheme on 2009-06-30. It is used to treat iron-deficiency anemia in the USA. It has been approved in Europe to treat anemia and chronic kidney failure.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Feraheme (generic drugs available since 2021-01-15)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ferumoxytol
Tradename
Company
Number
Date
Products
FERAHEMECovis PharmaN-022180 RX2009-06-30
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ferahemeNew Drug Application2020-09-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
iron-deficiency anemiaHP_0001891D018798D50
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ferumoxytol, Feraheme, Covis
65994982023-06-30DS, DP
ATC Codes
No data
HCPCS
Code
Description
Q0138
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
Q0139
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFERUMOXYTOL
INN—
Description
Iron(II,III) oxide, or black iron oxide, is the chemical compound with formula Fe3O4. It occurs in nature as the mineral magnetite. It is one of a number of iron oxides, the others being iron(II) oxide (FeO), which is rare, and iron(III) oxide (Fe2O3) which also occurs naturally as the mineral hematite. It contains both Fe2+ and Fe3+ ions and is sometimes formulated as FeO ∙ Fe2O3. This iron oxide is encountered in the laboratory as a black powder. It exhibits permanent magnetism and is ferrimagnetic, but is sometimes incorrectly described as ferromagnetic. Its most extensive use is as a black pigment (see: Mars Black). For this purpose, it is synthesized rather than being extracted from the naturally occurring mineral as the particle size and shape can be varied by the method of production.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=[Fe].O=[Fe]O[Fe]=O
Identifiers
PDB—
CAS-ID1317-61-9
RxCUI—
ChEMBL IDCHEMBL1201867
ChEBI ID—
PubChem CID16211978
DrugBankDB06215
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Feraheme - AMAG PHARMACEUTICALS, INC.
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,954 documents
View more details
Safety
Black-box Warning
Black-box warning for: Feraheme
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5 adverse events reported
View more details